Article · Wikipedia archive · Last revised Jul 17, 2026

Barbexaclone

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine. It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results" had not yet been confirmed nor denied in controlled trials.

Last revised
Jul 17, 2026
Read time
≈ 1 min
Length
208 w
Citations
4
Source
Wikipedia ↗
Barbexaclone
Combination of
PhenobarbitalBarbiturate
LevopropylhexedrineSympathomimetic
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.022.278
 X markNcheckY (what is this?)  (verify)

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.2 It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"3 had not yet been confirmed nor denied in controlled trials.

Potency

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.2

References

References

  1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
  3. Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi:10.1590/s0004-282x1978000300009. PMID 28716.
Further reading

Further reading